
Sri Lanka closes schools as floods hammer the capitalSri Lanka closes schools as floods hammer the capital Associated Press
||
COLOMBO, Sri Lanka — Sri Lanka closed schools in the capital Colombo and suburbs on Monday as heavy rains triggered floods in many parts of the island nation. Heavy... 
Crosspoint makes waves at Busan Film MarketCrosspoint makes waves at Busan Film Market Liza Diño-Seguerra
||
“Crosspoint” is set to redefine Filipino films globally. Representing this film as its sales agent for world sales, I’m thrilled to announce its success at the Asian Content &... 
Preliminary data on early redemptions (prepayments)Preliminary data on early redemptions (prepayments) GlobeNewswire
||
To Nasdaq Copenhagen A/S 14 October 2024 Announcement no. 85/2024 Preliminary data on early redemptions (prepayments) Pursuant to S. 24 of the Capital Markets Act, we hereby publish preliminary data... BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN)BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN) PR Newswire
||
SHANGHAI, Oct. 14, 2024 /PRNewswire/ — BioCity Biopharma announced that a late-breaking clinical trial abstract of its endothelin receptor type A (ETA) selective antagonist SC0062 has been selected for... 
Fortune Ranks Envision Among Top Global Companies Changing the World for Second TimeFortune Ranks Envision Among Top Global Companies Changing the World for Second Time PR Newswire
||
Envision recognized as Energy Innovator for its development of full-stack green hydrogen technologies worldwide The two-time ranking by Fortune underscores Envision’s relentless work globally to create a new renewable... 
KAZAKHSTAN TO HOST THE GAMES OF THE FUTURE 2026KAZAKHSTAN TO HOST THE GAMES OF THE FUTURE 2026 PR Newswire
||
DUBAI, UAE, Oct. 14, 2024 /PRNewswire/ — Following a highly competitive process, Phygital International today announces that Kazakhstan has been chosen as the host of the Games of the... 
Great Wall Global Unveils AI-Powered Products at Hong Kong Electronics FairGreat Wall Global Unveils AI-Powered Products at Hong Kong Electronics Fair PR Newswire
||
HONG KONG, Oct. 14, 2024 /PRNewswire/ — On October 13, the HKTDC Hong Kong Electronics Fair (Autumn Edition) welcomed global buyers and exhibitors. Great Wall Global (000066.SZ) made a... 
Major shareholder announcement – Pharma Equity Group A/SMajor shareholder announcement – Pharma Equity Group A/S GlobeNewswire
||
Major shareholder announcement – Pharma Equity Group A/S 14 October 2024 Announcement No. 28 Pharma Equity Group A/S has, in accordance with section 38 of the Capital... 
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the ReportInventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report GlobeNewswire
||
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on... 
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH studyInventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study GlobeNewswire
||
Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to...